{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T16:36:09Z","timestamp":1785256569687,"version":"3.55.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T00:00:00Z","timestamp":1636761600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Taiwanese Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.tjog.2021.11.015","type":"journal-article","created":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T18:21:13Z","timestamp":1644949273000},"page":"80-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Second primary malignancies after ovarian cancer: A SEER-based analysis (1975\u20132016)"],"prefix":"10.1016","volume":"61","author":[{"given":"Zihui","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin-Ping","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tjog.2021.11.015_bib1","doi-asserted-by":"crossref","first-page":"viii8","DOI":"10.1093\/annonc\/mdx445","article-title":"The new classifications of ovarian, fallopian tube, and primary peritoneal cancer and their clinical implications","volume":"28","author":"Duska","year":"2017","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.tjog.2021.11.015_bib2","first-page":"284","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"Ca - Cancer J Clin"},{"key":"10.1016\/j.tjog.2021.11.015_bib3","first-page":"280","article-title":"Epithelial ovarian cancer: evolution of management in the era of precision medicine","volume":"69","author":"Lheureux","year":"2019","journal-title":"Ca - Cancer J Clin"},{"key":"10.1016\/j.tjog.2021.11.015_bib4","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"Ca - Cancer J Clin"},{"key":"10.1016\/j.tjog.2021.11.015_bib5","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000018407","article-title":"CD247 expression is associated with differentiation and classification in ovarian cancer","author":"Ye","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.tjog.2021.11.015_bib6","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.thromres.2016.12.002","article-title":"Reciprocal links between venous thromboembolism, coagulation factors and ovarian cancer progression","volume":"150","author":"Swier","year":"2017","journal-title":"Thromb Res"},{"key":"10.1016\/j.tjog.2021.11.015_bib7","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.bpobgyn.2016.09.014","article-title":"Abnormal vaginal bleeding in women with gynaecological malignancies","volume":"40","author":"Adams","year":"2017","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1016\/j.tjog.2021.11.015_bib8","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1017\/S1478951515000127","article-title":"A\u00a0systematic review of ovarian cancer and fear of recurrence","volume":"13","author":"Ozga","year":"2015","journal-title":"Palliat Support Care"},{"key":"10.1016\/j.tjog.2021.11.015_bib9","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1136\/jech.2007.063560","article-title":"New malignancies among cancer survivors: SEER cancer registries, 1973\u20132000","volume":"62","author":"Supramaniam","year":"2008","journal-title":"J\u00a0Epidemiol Community Health"},{"key":"10.1016\/j.tjog.2021.11.015_bib10","doi-asserted-by":"crossref","first-page":"969","DOI":"10.21873\/anticanres.11406","article-title":"Synchronous endometrial and ovarian cancer in young women: case report and review of the literature","volume":"37","author":"Dogan","year":"2017","journal-title":"Anticancer Res"},{"key":"10.1016\/j.tjog.2021.11.015_bib11","doi-asserted-by":"crossref","DOI":"10.1097\/IGC.0000000000000950","article-title":"Epidemiology of second primary tumors in women with ovarian cancer","author":"Kanninen","year":"2017","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.tjog.2021.11.015_bib12","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/jnci\/61.5.1195","article-title":"Second primary neoplasms following ovarian cancer","volume":"61","author":"Reimer","year":"1978","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.tjog.2021.11.015_bib13","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jpag.2015.03.009","article-title":"Risk of second primary tumors after childhood and adolescent ovarian malignancies: a SEER analysis (1973-2011)","volume":"28","author":"Nasioudis","year":"2015","journal-title":"J\u00a0Pediatr Adolesc Gynecol"},{"key":"10.1016\/j.tjog.2021.11.015_bib14","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1186\/s12885-018-4700-3","article-title":"Second primary cancer after primary peritoneal, epithelial ovarian, and fallopian tubal cancer: a retrospective study","volume":"18","author":"Lim","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.tjog.2021.11.015_bib15","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/CEJ.0b013e3283240474","article-title":"Second neoplasms after invasive and borderline ovarian cancer","volume":"18","author":"Levi","year":"2009","journal-title":"Eur J Cancer Prev Off J Eur Cancer Prev Organ ECP"},{"key":"10.1016\/j.tjog.2021.11.015_bib16","article-title":"Surveillance, Epidemiology, and end results program","year":"2020","journal-title":"SEER"},{"key":"10.1016\/j.tjog.2021.11.015_bib17","first-page":"307","article-title":"International rules for multiple primary cancers (ICD-0 third edition)","volume":"14","year":"2005","journal-title":"Eur J Cancer Prev Off J Eur Cancer Prev Organ ECP"},{"key":"10.1016\/j.tjog.2021.11.015_bib18","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1158\/1055-9965.EPI-06-0414","article-title":"The Epidemiology of second primary cancers","volume":"15","author":"Travis","year":"2006","journal-title":"Cancer Epidemiol Prev Biomark"},{"key":"10.1016\/j.tjog.2021.11.015_bib19","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12874-017-0335-3","article-title":"Estimating the standardized incidence ratio (SIR) with incomplete follow-up data","volume":"17","author":"Becher","year":"2017","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.tjog.2021.11.015_bib20","first-page":"363","article-title":"Cancer treatment and survivorship statistics, 2019","volume":"69","author":"Miller","year":"2019","journal-title":"Ca - Cancer J Clin"},{"key":"10.1016\/j.tjog.2021.11.015_bib21","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ygyno.2011.07.097","article-title":"Therapy-related myeloid leukemia after treatment for epithelial ovarian carcinoma: an epidemiological analysis","volume":"123","author":"Vay","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.tjog.2021.11.015_bib22","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ygyno.2018.09.003","article-title":"Incidence of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with ovarian or breast cancer in a real-world setting in the United States","volume":"151","author":"Shenolikar","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.tjog.2021.11.015_bib23","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1053\/j.seminoncol.2013.09.013","article-title":"Therapy-related myelodysplasia and acute myeloid leukemia","volume":"40","author":"Bhatia","year":"2013","journal-title":"Semin Oncol"},{"key":"10.1016\/j.tjog.2021.11.015_bib24","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJM199902043400504","article-title":"Risk of leukemia after platinum-based chemotherapy for ovarian cancer","volume":"340","author":"Travis","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.tjog.2021.11.015_bib25","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ygyno.2018.10.013","article-title":"The impact of new drugs for breast and ovarian cancer on the occurrence of therapy-related myeloid neoplasms: understanding the baseline incidence","volume":"151","author":"Sella","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.tjog.2021.11.015_bib26","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.ygyno.2006.06.013","article-title":"Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study","volume":"102","author":"Bell","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.tjog.2021.11.015_bib27","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1001\/jamaoncol.2018.5625","article-title":"Association of chemotherapy for solid tumors with development of therapy-related myelodysplastic syndrome or acute myeloid leukemia in the modern era","volume":"5","author":"Morton","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.tjog.2021.11.015_bib28","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/IGC.0000000000000871","article-title":"Synchronous ovarian and appendiceal mucinous neoplasms in the absence of pseudomyxoma peritonei","volume":"27","author":"Gui","year":"2017","journal-title":"Int J Gynecol Cancer Off J Int Gynecol Cancer Soc"},{"key":"10.1016\/j.tjog.2021.11.015_bib29","first-page":"411","article-title":"Pseudomyxoma peritonei usually originates from the appendix: a review of the evidence","volume":"25","author":"Mukherjee","year":"2004","journal-title":"Eur J Gynaecol Oncol"},{"key":"10.1016\/j.tjog.2021.11.015_bib30","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1136\/ijgc-00009577-200801000-00009","article-title":"Mucinous ovarian tumors associated with pseudomyxoma peritonei of adenomucinosis type: immunohistochemical evidence that they are secondary tumors","volume":"18","author":"Ferreira","year":"2008","journal-title":"Int J Gynecol Cancer Off J Int Gynecol Cancer Soc"},{"key":"10.1016\/j.tjog.2021.11.015_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00004347-199701000-00001","article-title":"Immunohistochemical evidence supporting the appendiceal origin of pseudomyxoma peritonei in women","volume":"16","author":"Ronnett","year":"1997","journal-title":"Int J Gynecol Pathol Off J Int Soc Gynecol Pathol"},{"key":"10.1016\/j.tjog.2021.11.015_bib32","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1002\/1097-0142(19921215)70:12<2980::AID-CNCR2820701240>3.0.CO;2-O","article-title":"Concomitant mucinous tumors of appendix and ovary. Result of a neoplastic field change?","volume":"70","author":"Sumithran","year":"1992","journal-title":"Cancer"},{"key":"10.1016\/j.tjog.2021.11.015_bib33","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/00000478-199301000-00003","article-title":"Association of mucinous tumors of the ovary and appendix. A clinicopathologic study of 25 cases","volume":"17","author":"Seidman","year":"1993","journal-title":"Am J Surg Pathol"},{"issue":"46","key":"10.1016\/j.tjog.2021.11.015_bib34","first-page":"e1","article-title":"The role of appendectomy for mucinous ovarian neoplasms","volume":"208","author":"Lin","year":"2013","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2021.11.015_bib35","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/0090-8258(92)90193-M","article-title":"The role of appendectomy in surgical procedures for ovarian cancer","volume":"46","author":"Fontanelli","year":"1992","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.tjog.2021.11.015_bib36","doi-asserted-by":"crossref","first-page":"24237","DOI":"10.18632\/oncotarget.10757","article-title":"Crosstalk between integrin \u03b1v\u03b23 and ER\u03b1 contributes to thyroid hormone-induced proliferation of ovarian cancer cells","volume":"8","author":"Hsieh","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.tjog.2021.11.015_bib37","doi-asserted-by":"crossref","first-page":"16475","DOI":"10.1038\/s41598-017-16593-x","article-title":"Thyroid hormones derivatives reduce proliferation and induce cell death and DNA damage in ovarian cancer","volume":"7","author":"Shinderman-Maman","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.tjog.2021.11.015_bib38","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/mc.22735","article-title":"Molecular insights into the transcriptional regulatory role of thyroid hormones in ovarian cancer","volume":"57","author":"Shinderman-Maman","year":"2018","journal-title":"Mol Carcinog"},{"key":"10.1016\/j.tjog.2021.11.015_bib39","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s12325-019-00918-5","article-title":"Thyroid cancer benefits the prognosis of ovarian cancer: a SEER-based study","volume":"36","author":"Yang","year":"2019","journal-title":"Adv Ther"},{"key":"10.1016\/j.tjog.2021.11.015_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ijc.2910630102","article-title":"Bladder tumours following chemotherapy and radiotherapy for ovarian cancer: a case-control study","volume":"63","author":"Kaldor","year":"1995","journal-title":"Int J Cancer"},{"key":"10.1016\/j.tjog.2021.11.015_bib41","doi-asserted-by":"crossref","first-page":"189","DOI":"10.7326\/0003-4819-131-3-199908030-00005","article-title":"Risk for colorectal cancer after gynecologic cancer","volume":"131","author":"Weinberg","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.tjog.2021.11.015_bib42","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S0140-6736(94)91578-4","article-title":"Risks of cancer in BRCA1-mutation carriers. Breast cancer linkage consortium","volume":"343","author":"Ford","year":"1994","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.tjog.2021.11.015_bib43","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11912-001-0039-y","article-title":"Genetic factors in ovarian carcinoma","volume":"3","author":"Li","year":"2001","journal-title":"Curr Oncol Rep"}],"container-title":["Taiwanese Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1028455921003193?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1028455921003193?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T18:20:47Z","timestamp":1760898047000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1028455921003193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S1028455921003193"],"URL":"https:\/\/doi.org\/10.1016\/j.tjog.2021.11.015","relation":{},"ISSN":["1028-4559"],"issn-type":[{"value":"1028-4559","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Second primary malignancies after ovarian cancer: A SEER-based analysis (1975\u20132016)","name":"articletitle","label":"Article Title"},{"value":"Taiwanese Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjog.2021.11.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Taiwan Association of Obstetrics & Gynecology. Publishing services by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}